Overview

Price chart · mood · technical indicators

PFE

Pfizer Incstock Healthcare

Drug Manufacturers - General

$25.225.21%Current Market Mood:Neutral

Market Mood

Price Range (1Y)

$23.11$28.75

Current: $25.22

Market Comparison

vs Healthcare Sector & Drug Manufacturers - General Industry

PFE

+5.21%

1Y Performance

Healthcare

Sector 1Y

Drug Manufacturers - General

Industry 1Y

Fundamentals

Updated daily after market close

P/E ratio19.79Forward 8.79

EPS (TTM)$1.31-10.1% YoY

Profit margin11.8%HEALTHCARE

Market cap$147.73BLarge cap

Wall Street coverage

$29.19median target· current $27.74 (+5.2%)29 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: 8.79
PEG ratio: 3.77
P/B: 1.64
P/S (TTM): 2.33
EV/EBITDA: 11.55

Profitability & growth

ROE (TTM): 8.3%
Operating margin: 31.6%
Revenue growth YoY: 5.4%
Dividend yield: 6.6%
Beta: 0.29

Last earnings

May 5, 2026 · Estimate $0.72 · Reported $0.75

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

19 articles · sorted by date

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Pfizer Inc

Company profile

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Classification

Sector: Healthcare
Industry: Drug Manufacturers - General
Exchange: NYSE
Country: USA
Currency: USD

Company profile

HQ: 66 HUDSON BOULEVARD EAST, NEW YORK, NY
Fiscal year end: December
Latest quarter: Mar 31, 2026

Market cap$147.73B

Shares outstanding$5.70B

52W high$28.28

52W low$21.97

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer

Overview

PFE

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Vascular Dementia Market Unlocking New Revenue Opportunities and Strategic Expansion by 2034 – DelveInsight | Pfizer, Gilead Sciences, ViiV Healthcare

Pfizer Stock Drops Today As CFO Steps Down In August

Pfizer Inc. stock underperforms Thursday when compared to competitors

Pfizer (PFE) Shares Sink After Surprise CFO Exit

Living Longer with Cancer: Redefining What It Means to Survive

Pfizer Launches CFO Search as Denton Plans to Depart in August

Pfizer stock in focus as CFO plans to resign (PFE:NYSE)

Pfizer CFO Dave Denton to step down, leave company in August

Pfizer Announces Chief Financial Officer Transition

Pfizer Announces Chief Financial Officer Transition

Pfizer CFO Dave Denton to step down in August

Amneal Pharmaceuticals Inc (AMRX) Shareholder Structure: Major Shareholders & Institutional Holdings

Pfizer Stock And Two AI Healthcare Plays That Look Mispriced

Questions over Pfizer’s marketing claims resurface as scrutiny grows around blockbuster drug promotion

Rigel to roll out Veppanu in August; Arvinas, Pfizer snag $70M upfront on cleared deal

According to a filing submitted to the U.S. Securities and Exchange Commission, biotechnology company Arvinas Holding Company LLC, pharmaceutical giant Pfizer, and Rigel Pharmaceuticals obtained approval under the Hart–Scott–Rodino Antitrust Improv

Pfizer trades up with Rigel’s Veppanu deal done

Arvinas, Pfizer receive $70M upfront as Rigel deal for VEPPANU clears HSR

Pfizer’s Dividend Has Grown Every Year Since 2021, and the Stock Still Yields Over 6%

About Pfizer Inc

Classification

Company profile

PFE

Market Comparison

PFE Market Analysis

Overview

PFE

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Vascular Dementia Market Unlocking New Revenue Opportunities and Strategic Expansion by 2034 – DelveInsight | Pfizer, Gilead Sciences, ViiV Healthcare

Pfizer Stock Drops Today As CFO Steps Down In August

Pfizer Inc. stock underperforms Thursday when compared to competitors

Pfizer (PFE) Shares Sink After Surprise CFO Exit

Living Longer with Cancer: Redefining What It Means to Survive

Pfizer Launches CFO Search as Denton Plans to Depart in August

Pfizer stock in focus as CFO plans to resign (PFE:NYSE)

Pfizer CFO Dave Denton to step down, leave company in August

Pfizer Announces Chief Financial Officer Transition

Pfizer Announces Chief Financial Officer Transition

Pfizer CFO Dave Denton to step down in August

Amneal Pharmaceuticals Inc (AMRX) Shareholder Structure: Major Shareholders & Institutional Holdings

Pfizer Stock And Two AI Healthcare Plays That Look Mispriced

Questions over Pfizer’s marketing claims resurface as scrutiny grows around blockbuster drug promotion

Rigel to roll out Veppanu in August; Arvinas, Pfizer snag $70M upfront on cleared deal

According to a filing submitted to the U.S. Securities and Exchange Commission, biotechnology company Arvinas Holding Company LLC, pharmaceutical giant Pfizer, and Rigel Pharmaceuticals obtained approval under the Hart–Scott–Rodino Antitrust Improv

Pfizer trades up with Rigel’s Veppanu deal done

Arvinas, Pfizer receive $70M upfront as Rigel deal for VEPPANU clears HSR

Pfizer’s Dividend Has Grown Every Year Since 2021, and the Stock Still Yields Over 6%

About Pfizer Inc

Classification

Company profile

PFE

Market Comparison